Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Dysregulation of the mitosis-meiosis switch in testicular carcinoma in situ

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Endocytic collagen degradation: A novel mechanism involved in the protection against liver fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The collagen receptor uparap in malignant mesothelioma: A potential diagnostic marker and therapeutic target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In osteosarcoma, a primary mesenchymal bone cancer occurring predominantly in younger patients, invasive tumor growth leads to extensive bone destruction. This process is insufficiently understood, cannot be efficiently counteracted and calls for novel means of treatment. The endocytic collagen receptor, uPARAP/Endo180, is expressed on various mesenchymal cell types and is involved in bone matrix turnover during normal bone growth. Human osteosarcoma specimens showed strong expression of this receptor on tumor cells, along with the collagenolytic metalloprotease, MT1-MMP. In advanced tumors with ongoing bone degeneration, sarcoma cells positive for these proteins formed a contiguous layer aligned with the degradation zones. Remarkably, osteoclasts were scarce or absent from these regions and quantitative analysis revealed that this scarcity marked a strong contrast between osteosarcoma and bone metastases of carcinoma origin. This opened the possibility that sarcoma cells might directly mediate bone degeneration. To examine this question, we utilized a syngeneic, osteolytic bone tumor model with transplanted NCTC-2472 sarcoma cells. When analyzed in vitro, these cells were capable of degrading the protein component of surface-labeled bone slices in a process dependent on MMP activity and uPARAP/Endo180. Systemic treatment of the sarcoma-inoculated mice with a mouse monoclonal antibody that blocks murine uPARAP/Endo180 led to a strong reduction of bone destruction. Our findings identify sarcoma cell-resident uPARAP/Endo180 as a central player in the bone degeneration of advanced tumors, possibly following an osteoclast-mediated attack on bone in the early tumor stage. This points to uPARAP/Endo180 as a promising therapeutic target in osteosarcoma with particular prospects for improved neoadjuvant therapy.

TidsskriftThe Journal of pathology
Sider (fra-til)120-133
StatusUdgivet - 2016

ID: 45783689